NEW YORK (GenomeWeb) – Emerging biotechnology company Locus Biosciences announced today that it has closed a $5 million convertible note, and will use the funds to support the development of antimicrobial therapeutics based on CRISPR-Cas3 technology.

Financing for the round was led by Chinese Internet services provider Tencent Holdings and was joined by the North Carolina Biotechnology Center. Locus said the funding will help it advance development on several infectious disease products targeting antibiotic resistant infections and other microbiome-related diseases.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.